{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'onset period will be analyzed and compared using the same model as used in the primary analysis.', 'The change from baseline in physical health score and total score of Haem-A-QOL will be analyzed', 'using an analysis of covariance (ANCOVA) model with fixed effects of the treatment arm, baseline', 'Haem-A-QOL physical health score and total score, and the number of bleeding episodes in the', '6 months prior to study entry (10 vs >10) as covariates.', 'Familywise error rate will be strongly controlled for the primary endpoint and the selected secondary', 'endpoints using a fixed sequence testing procedure.', 'Safety results will be summarized descriptively.', 'Property of the Sanofi Group - strictly confidential', '11']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Table 1:', 'Schedule of Assessments', 'Treatment Period', 'Onset', 'AT', 'Period', 'Efficacy Period', 'F/Ub,c', 'EOS/', 'EOT', 'ETa,b', 'Study Visit (Month)', 'Study Day (Visit Window)', 'Informed Consent/Assent', 'X', 'Medical Historyd', 'Demographics', 'Inclusion/Exclusion Criteria', 'Randomization', 'eDiary Training', 'Physical Examination8', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Body Weight and Heighth', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Vital Signs', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', \"12-Lead ECG'\", 'X', 'X', 'FibroScan OR FibroTest/APRF', 'TG Levelk,1', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Coagulation', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Nijmegen-Modified Bethesda', 'X', 'Xm', 'Assay (Inhibitor Status)', 'AT Activity Levelk,1,', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'FVIII / FIX Levelsk', 'X', 'Thrombophilia Screening', 'Property of the Sanofi Group - strictly confidential', '12']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Table 1:', 'Schedule of Assessments', 'Treatment Period', 'Onset', 'AT', 'Period', 'Efficacy Period', 'F/Ub,c', 'EOS/', 'EOT', 'ETa,b', 'Study Visit (Month)', 'Study Day (Visit Window)', 'Serum Chemistry', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Liver Function Testsp', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Anti-Drug', 'X', 'X', 'X', 'Xm', 'Hematology', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Hepatic TestsP', 'Exploratory Biomarkers', 'X', 'X', 'X', 'Exploratory Circulating RNA', 'X', 'X', 'X', '(Optional)*', 'Exploratory DNA Sample', 'X', '(Optional) k', 'Plasma PKK,', 'X', 'X', 'X', 'X', 'X', 'Urinalysis', 'X', 'X', 'Urine Collection for', 'X', 'Biomarkers*', 'X', 'X', 'HJHS', 'X', 'X5', 'Patient Resource Use5', 'X', 'X5', 'EQ-5D5', 'X', 'XX', 'Haem-A-QOL/Haemo-QOLS', 'X', 'X5', 'HAL / pedHAL5', 'X', 'Xs', 'Property of the Sanofi Group - strictly confidential', '13']\n\n###\n\n", "completion": "END"}